PTC Therapeutics Announces Initiation of Phase 2/3 Clinical Trial in Australia to Evaluate PTC299 for the Treatment of COVID-19-PR Newswire APAC

– Oral treatment with novel dual-mechanism of action has the potential to address the two critical elements of COVID-19: viral replication and uncontrolled inflammatory response –

– Randomized, double-blind, placebo-controlled, Phase 2/3 clinical study with two stages initiated at several sites in Australia –

– Also...

Read more: PTC Therapeutics Announces Initiation of Phase 2/3 Clinical Trial in Australia to Evaluate PTC299 fo...

More Articles …

  1. Lifestyle Hotel Brand TRYP by Wyndham Takes its Inaugural Trip to New Zealand-PR Newswire APAC
  2. The third CIIE concludes, $72.6 billion in intended deals for the coming year inked-PR Newswire APAC
  3. The fourth CIIE begins taking stall reservations from exhibitors-PR Newswire APAC
  4. Infosys Positioned as a Leader in the Everest Group PEAK Matrix® for Cloud-native Application Development Service Providers 2020-PR Newswire APAC
  5. Egis and Cylus Partner to launch a Center of Excellence, for Rail Cybersecurity Services-PR Newswire APAC
  6. Integrating Fitbit Wearable Devices into Diabetes Care Leads to Significant Improvements in Blood Glucose and HbA1C, Finds Health2Sync Clinical Study in Taiwan
  7. MessageMedia and Marquis Software announce study that shows text messaging appointment reminders reduce community corrections no-shows by 43%
  8. FlexRule Recognized by a Leading Research Firm in The Report on Digital Decisioning Platforms-PR Newswire APAC
  9. Award-winning Director Anthony Wonke's New Feature Documentary on Johnnie Walker Serves up a Measure of Spirit for our Times-PR Newswire APAC
  10. SOR Licenses CSIRO Technology for Robotic Security Teams-PR Newswire APAC